Walvax BioTech (300142) - Total Assets
Based on the latest financial reports, Walvax BioTech (300142) holds total assets worth CN¥11.13 Billion CNY (≈ $1.63 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Walvax BioTech long-term investment allocation to see how much of total assets are deployed in long-term investments.
Walvax BioTech - Total Assets Trend (2007–2025)
This chart illustrates how Walvax BioTech's total assets have evolved over time, based on quarterly financial data. Check 300142 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Walvax BioTech - Asset Composition Analysis
Current Asset Composition (December 2025)
Walvax BioTech's total assets of CN¥11.13 Billion consist of 37.7% current assets and 62.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 11.2% |
| Accounts Receivable | CN¥2.29 Billion | 19.0% |
| Inventory | CN¥574.16 Million | 4.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.37 Billion | 11.4% |
| Goodwill | CN¥33.66 Million | 0.3% |
Asset Composition Trend (2007–2025)
This chart illustrates how Walvax BioTech's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 300142 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Walvax BioTech's current assets represent 37.7% of total assets in 2025, a decrease from 47.2% in 2007.
- Cash Position: Cash and equivalents constituted 11.2% of total assets in 2025, down from 12.1% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 9.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 19.0% of total assets.
Walvax BioTech Competitors by Total Assets
Key competitors of Walvax BioTech based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424
|
China | CN¥5.95 Billion |
Walvax BioTech - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.16 | 3.27 | 3.16 |
| Quick Ratio | 1.88 | 2.93 | 2.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.33 Billion | CN¥4.69 Billion | CN¥3.83 Billion |
Walvax BioTech - Advanced Valuation Insights
This section examines the relationship between Walvax BioTech's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.88 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | -18.0% |
| Total Assets | CN¥12.07 Billion |
| Market Capitalization | $3.10 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Walvax BioTech's assets below their book value (0.26x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Walvax BioTech's assets decreased by 18.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Walvax BioTech (2007–2025)
The table below shows the annual total assets of Walvax BioTech from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥12.07 Billion ≈ $1.77 Billion |
-18.02% |
| 2024-12-31 | CN¥14.72 Billion ≈ $2.15 Billion |
-5.55% |
| 2023-12-31 | CN¥15.59 Billion ≈ $2.28 Billion |
+1.65% |
| 2022-12-31 | CN¥15.34 Billion ≈ $2.24 Billion |
+12.15% |
| 2021-12-31 | CN¥13.67 Billion ≈ $2.00 Billion |
+41.73% |
| 2020-12-31 | CN¥9.65 Billion ≈ $1.41 Billion |
+37.48% |
| 2019-12-31 | CN¥7.02 Billion ≈ $1.03 Billion |
-3.14% |
| 2018-12-31 | CN¥7.24 Billion ≈ $1.06 Billion |
+23.30% |
| 2017-12-31 | CN¥5.88 Billion ≈ $859.84 Million |
-7.08% |
| 2016-12-31 | CN¥6.32 Billion ≈ $925.40 Million |
+1.06% |
| 2015-12-31 | CN¥6.26 Billion ≈ $915.72 Million |
+4.86% |
| 2014-12-31 | CN¥5.97 Billion ≈ $873.26 Million |
-2.74% |
| 2013-12-31 | CN¥6.14 Billion ≈ $897.87 Million |
+37.88% |
| 2012-12-31 | CN¥4.45 Billion ≈ $651.21 Million |
+47.99% |
| 2011-12-31 | CN¥3.01 Billion ≈ $440.03 Million |
+0.69% |
| 2010-12-31 | CN¥2.99 Billion ≈ $437.01 Million |
+673.44% |
| 2009-12-31 | CN¥386.12 Million ≈ $56.50 Million |
+27.90% |
| 2008-12-31 | CN¥301.90 Million ≈ $44.18 Million |
+38.79% |
| 2007-12-31 | CN¥217.52 Million ≈ $31.83 Million |
-- |
About Walvax BioTech
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, grou… Read more